It must also be confirmed whether plasma AM level can be used as a biomarker for predicting the long-term prognosis of patients suffering from nasopharyngeal carcinoma, whether AM expression can be used to evaluate the prognosis and malignant potential in human ovarian cancer, and whether AM2 expression can be used to predict survival in pancreatic cancer [240,249,260]. This evidence concerns the gene ADM2 and pancreatic neoplasm.